Northwire Canada EditionTuesday, August 25, 2026
Northwire
GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% NVO 0.070 +0.0% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0% GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% NVO 0.070 +0.0% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0%
Other Routine +

Promino Launches Muscle Health Research Initiative Targeting GLP-1 Weight Management Market

MUSL · Price

Executive Summary

  • Promino Nutritional Sciences announced the planned launch of its first Muscle Health Research Initiative, marking a strategic step toward generating proprietary human evidence for its product portfolio.
  • The initiative centers on an 8-week real-world evaluation study of its flagship product, Rejuvenate Muscle Health™, targeting approximately 50 adults currently using GLP-1 weight management therapies.
  • The study aims to assess product adherence, functional muscle-health metrics, nutritional intake, and participant-reported outcomes, with results intended to support expansion into weight management, healthy aging, and sports performance markets.

Key Details

  • Study Scope: First Muscle Health Research Initiative; real-world evaluation study.
  • Product Tested: Rejuvenate Muscle Health™ (flagship brand, available at www.drinkrej.com).
  • Target Cohort: Approximately 50 adults currently prescribed GLP-1 medications under physician-supervised weight management programs.
  • Study Duration: 8 weeks.
  • Assessment Metrics: Product adherence, functional muscle-health measures, nutritional intake patterns, and participant-reported outcomes.
  • Execution Partner: To be conducted in collaboration with an independent research or clinical partner.
  • Strategic Objective: Generate proprietary human evidence to support the broader muscle health platform across weight management, healthy aging, active lifestyle, and sports performance segments.
  • Product Portfolio Context: Platform includes Rejuvenate Muscle Health™ (everyday consumers) and Promino™ NSF Certified for Sport® (athletes/performance-focused individuals).
  • Future Reporting: Company expects to provide periodic updates on study initiation, enrollment progress, and completion.

Notable Quotes

  • Vito Sanzone, CEO: "The rapid adoption of GLP-1 therapies has increased awareness around the importance of maintaining muscle health and adequate nutrition during weight-loss programs. Our objective is to build a leading proprietary muscle health platform supported by differentiated formulations, commercial execution and scientific evidence. Rejuvenate Muscle Health™ is the cornerstone of that strategy, and this initiative is designed to generate real-world insights that support the continued development of the brand and our broader muscle health platform."
Read the original news release →

More from Promino Nutritional Sciences Inc